Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

Objectives Programmed cell death-ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) have achieved substantial progress in extensive-stage small-cell lung cancer (ES-SCLC). However, evidence about programmed cell death 1 inhibitors plus chemotherapy (PD-1 + Chemo) in SCLC is relatively lacking. Wh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2022-03, Vol.71 (3), p.637-644
Hauptverfasser:	Yu, Hui, Chen, Ping, Cai, Xiuyu, Chen, Chen, Zhang, Xuanye, He, Lina, Zhou, Yixin, Hong, Shaodong, Zhang, Bei
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis B7-H1 Antigen - antagonists & inhibitors Brain cancer Cancer Research Cell death Chemotherapy Clinical trials Disease Management Disease Susceptibility Humans Immune Checkpoint Inhibitors - administration & dosage Immunology Lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - etiology Lung Neoplasms - metabolism Medicine Medicine & Public Health Metastases Molecular Targeted Therapy Neoplasm Metastasis Neoplasm Staging Odds Ratio Oncology Original Original Article Patients PD-1 protein PD-L1 protein Pneumonia Prognosis Programmed Cell Death 1 Receptor - antagonists & inhibitors Safety Small cell lung carcinoma Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - etiology Small Cell Lung Carcinoma - metabolism Small Cell Lung Carcinoma - pathology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!